Topic Summary
The link between obesity and obstructive sleep apnoea (OSA) is firmly established. And now, with the advent of effective obesity incretin therapies, what does that mean for the management of OSA? And where does that leave CPAP therapy? In this article, OSA expert, Prof Brendon Yee, provides an update on OSA and its association with obesity. He also discusses the role of obesity therapeutics for this condition – the evidence, the indications, the logistics and the future possibilities.
Learning Objectives
- Identify appropriate patients with OSA for whom incretin therapy might be appropriate
- Examine the efficacy of tirzepatide as an adjunct or possibly first line option for OSA
- Review the limitations, both in terms of clinical trial data as well as comparative efficacy of incretins vis a vis other options for OSA treatment
Featured Expert
Prof Brendon Yee
Respiratory and Sleep Medicine Physician; Woolcock Institute of Medical Research; Staff Specialist and Medical Director of Respiratory Failure Services, Royal Prince Alfred Hospital; Consultant, Rural Outreach Services
CPD and Accreditation
This activity is accredited with the RACGP and ACRRM for the following hours:
- 0.5 hours in the Educational Activities (EA)
- 0.5 hours Reviewing Performance (RP)
- 1 hour Measuring Outcomes (MO)
Disclosure Statement
Proudly supported by an independent educational grant from Lilly.
